Blueprint Medicines Analyst Ratings
Morgan Stanley Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $115
Blueprint Medicines (BPMC) Receives a Hold From Morgan Stanley
Oppenheimer Adjusts Price Target on Blueprint Medicines to $125 From $114, Maintains Outperform Rating
Blueprint Medicines Analyst Ratings
Blueprint Medicines Analyst Ratings
Blueprint Medicines Analyst Ratings
Blueprint Medicines Analyst Ratings
Blueprint Medicines Analyst Ratings
Blueprint Medicines Analyst Ratings
JMP Securities Maintains Market Outperform on Blueprint Medicines, Raises Price Target to $125
Wells Fargo Remains a Buy on Blueprint Medicines (BPMC)
Sell/High Risk: Cautious Outlook on Blueprint Medicines Amidst Unsustainable Growth Factors
Ayvakit's Sales Surge Supports Buy Rating and Increased Price Target for Blueprint Medicines
Blueprint Medicines Analyst Ratings
Buy Rating Affirmed for Blueprint Medicines on Strong Financials and Clinical Pipeline Prospects
Wedbush Raises Blueprint Medicines' Price Target to $120 From $110 After Stronger-Than-Expected Q1 Results, Keeps Outperform Rating
Blueprint Medicines Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: 10x Genomics (TXG), Zoetis (ZTS) and Blueprint Medicines (BPMC)
Analysts Offer Insights on Healthcare Companies: Hookipa Pharma (HOOK), Praxis Precision Medicines (PRAX) and Blueprint Medicines (BPMC)